InflaRx IFRX · USD

Its shares trade under the ticker IFRX. It has been listed since 16 November 2017. In the fiscal year to 31 December 2025, it reported revenue of €29,331 and a net loss of €45.6m. At that date it held total assets of €55.2m and shareholders' equity of €41.6m.

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Nicolas FulpiusIndependent Chairman of the Board
• Prof. Niels RiedemannChief Executive Officer, Executive Director, since 2007
• Dr. Thomas TaapkenChief Financial Officer
• Ms. Derval O'CarrollSenior Vice President, Global Head of Regulatory Affairs and Compliance
• Prof. Renfeng GuoChief Scientific Officer, Executive Director, since 2007
• Dr. Camilla ChongChief Medical Officer
• Mr. Richard BrudnickNon-Executive Independent Director
• Mr. Anthony GibneyNon-Executive Independent Director
• Ms. Hege HellstromNon-Executive Independent Director
• Mr. Mark KublerNon-Executive Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.